International Life Sciences Chair Cheryl Reicin recently joined the Scrip M&A Podcast to share insights on the evolving landscape of biopharmaceutical mergers and acquisitions. In the episode, Cheryl highlights an uptick in pre-M&A activity, as major pharmaceutical companies increasingly leverage license and option agreements to strengthen their pipelines and product portfolios while positioning themselves for potential future acquisitions. 

Commenting on the current deal environment, Cheryl notes, “I think we have to look at the whole ecosystem when we say it’s not healthy. I think the pharmas want to reduce their risk in an environment of some uncertainty, but they’re still planning so that they have opportunities, and they’re putting a lot of shots on goal right now so that they will have acquisitions in the near future.”

Source

Scrip M&A Podcast